Member Info for moorlaner

AVA6000 is a delivery mechanism, simples. Dox is already approved even though it has very significant side effects in its current form. The FDA have a simple decision to make that lessens the toxicities of a drug they have already approved.

Nice day to put a member of the clergy in the green box. bye bye vicar

Avacta certainly has not got no patience it is the Posters on this Message Board. (scuse the pun).. We have a delivery mechanism which is now definitely proved to work. It is delivering a chemo which is already approved worldwide and used extensively. The next phase is obviously needed to inform the optimum regime for maximum patient benefit. 2 weekly dosing at a level with no adverse events is next. Perhaps daily dosing at low levels for tumours that are detected early will become an option. It is just a matter of time before the share price reacts, and it will probably be to a Big Pharma involvement. When I asked an AI tool who makes Doxirubicin its first answer was Pfizer in the USA. Avacta seem to be concentrating on the USA at the moment......

Frasers hold a larger percentage in ASOS than they do in Boo. Perhaps they will carry on picking up shares in each at the current depressed levels and when the time is optimum encourage a merger???

DU. great post, but I have exhibited the patience of a saint with this one, and I am getting restless. I think I will give it another 6 months and then revaluate.

Waited too long here. sold and bought greenroc.

Only thing that is going to save WINE is a take over, but who would want it? -- AMAZON

Rowan Gormley as Chair is a significant change and I think a very positive one. Tempted to top up !!

Will 19.88% do .......................

Based on progress to date I will show my backside in Woolworth's window if they ever achieve all of those ................

Just joined the shareholders list (in a modest way) . Hoping to be less modest once JOG come good! Many thx for the informed debate on this board and detailed explanations

Dick, all the best to you and fellow joggers for the new year.

My sentiments exactly. I might only be a small shareholder but I will never be a customer of theirs ever again. I wouldn't have their stuff even if they give it away.

I think Graphite rather than gold is going to be our salvation .

"No-one is concerned about pipeline updates. What concerns some of us is lack of info on cashflow and accurate closure dates. Can we make first big repayment on 29th Aug? No news on that."

I am not aware of many companies give running cashflow updates, and none that give accurate closure dates. If that is the info you require then it will be a case of being continually disappointed regardless of which company you are invested in. As for the payment on the 29th then you only have to stress for another 7 days on that one.!!

Progress might be slow for those looking for a quick bagger BUT I do like the openess of the information we get as shareholders. Not many companies are so forthcoming about their sales pipeline. To me it shows that they have a sharp eye on how to succeed. As for PHE then one day Rodders seems to be the company motto.

it doesn't say it works. I would conjecture that NC is involved in a variety of P1 trials.

Baffyman, never deramped in my life. look at any of my previous posts. I was hoping for some serious responses from the questions I posed. Perhaps other responses will be more helpful.

Do not get me wrong when you read this, I wish as much as anyone that this cleaving works. Even more than many of you because I have a very close relative who would benefit from a drug delivery mechanism that works. Also, but of absolutely no consequence in the grand scheme of life, I have a significant percentage (15%) of my portfolio invested in Avacta.

But I do have concerns. Those concerns are based on my experience of the AIM market of the last few years. Three risky investments have recently completely let me down, Sirius, ODX, and 4DDDD. On all their message boards the authors expressing caution were regularly criticised. Also having an emotional attachment to the shares tended me to read the positive posts more than the cautionary tales.

On this message board there are some staunch defenders of the stock and I would like to raise some questions to help me avoid emotional decision making. Most of the abusers are already green boxed so don’t waste your time responding.

The first dosing was August 11th 2021. So at nearly 12 months we approach a critical moment. What if the approach means that the release of Doxirubicin is negligible/nil?. It would mean that the Phase 1 would be successful as that was what it was meant to test, was it not? ie what is the maximum dose that is tolerable the MTD. If as recently suggested there is not likely to be a MTD identified then could that mean it doesn’t release into the body at all? Would the recruitment of more cohorts not be part of the rigor needed for it to be a statistically valid trial? Would the development of PET scan testing imply that the actual cleaving is not easy to detect. And finally is it possible that it only delivers doxi to the extremities of the tumours?

AS received such a mauling on this board for the Virus diagnostics that I am sure he is being extremely cautious. So when he says it is proceeding very well I am reassured somewhat. Does that mean that it works, and not that the trial has merely proved the drugs can be delivered in larger doses than conventionally dished out ie efficacy has not yet been tested.

GLA

Dick enjoy your birthday. Thank you for your informative posts.